[1]李德霞 李琳.白介素-1β与心力衰竭的研究进展[J].心血管病学进展,2020,(6):591.[doi:10.16806/j.cnki.issn.1004-3934.2020.06.008]
　LI Dexia LI Lin.Interleukin-1 and Heart Failure[J].Advances in Cardiovascular Diseases,2020,(6):591.[doi:10.16806/j.cnki.issn.1004-3934.2020.06.008]
点击复制

白介素-1β与心力衰竭的研究进展()
分享到：

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2020年6期
页码:
591
栏目:
综述
出版日期:
2020-06-25

文章信息/Info

Title:
Interleukin-1 and Heart Failure
作者:
李德霞1 李琳 2
1.昆明医科大学研究生院,云南 昆明 650000;2.昆明医科大学第一附属医院心内科,云南 昆明 650000)
Author(s):
LI Dexia 1 LI Lin2
Kunming Medical University Graduate School , Kunming 650000, Yunnan, China; 2. Department of Cardiology, The First Affiliated Hospital of Kunming Medical UniversityKunming 650000YunnanChina)
关键词:
白细胞介素-1β; 心力衰竭; 炎症反应
Keywords:
Interleukin-1; Heart Failure; Inflammatory
DOI:
10.16806/j.cnki.issn.1004-3934.2020.06.008
摘要:
白介素-1β（IL-1β）作为高效致炎因子，在炎症反应中处于核心地位。大量研究表明，IL-1β参与心室重构，造成心肌细胞凋亡，影响心脏收缩舒张功能，在心力衰竭病理生理机制和疾病进展中发挥重要作用。IL-1β阻滞剂能中和IL-1β的生物学效应，有望成为心力衰竭治疗新靶点。现就IL-1β与心力衰竭的相关研究进展进行系统阐述。
Abstract:
Interleukin-1β(IL-1β), as a highly effective inflammatory factor, is at the core of the inflammatory response. A large number of studies have shown that IL-1β induces cardiac remodeling, causes cardiomyocyte apoptosis, and exerts negative effects on systolic and diastolic function of the cardiac. IL-1β plays an important role in the pathogenesis and progression of heart failure. IL-1β blockers neutralize the activity of IL-1β, and it is expected to be a new target for the treatment of heart failure. This review summarizes the current published data on the associations between IL-1β and heart failure

参考文献/References:

[1] 中华医学会心血管病学分会心力衰竭学组,中国医师协会心力衰竭专业委员会,中华心血管病杂志编辑委员会.《中国心力衰竭诊断和治疗指南2018》[J].中华心血管病杂志,2018,46(10):760-789.

[2] 胡盛寿,高润霖,刘力生,等.《中国心血管病报告2018》概要[J].中国循环杂志,2019,34(3):209-220.

[3] Ponikowski P,Anker SD,Alhabib KF,et al. Heart failure: preventing disease and death worldwide[J]. ESC Heart Failure,2014,1(1):4-25.

[4] Linthout S,TschoPe C. Inflammation-cause or consequence of heart failure or both?[J]. Curr Heart Fail Rep,2017,14(4):251-265.

[5] Williams JW ,Li H,Randolph G. Cytokine circuits in cardiovascular disease[J].Immunity,2019,50(4):941-954.

[6] Garlanda C,Dinarello C,Mantovani A.The interleukin-1 family:back to the future[J]. Immunity,2013,39(6):1003-1018.

[7] Libby P. Interleukin-1 beta as a target for atherosclerosis therapy[J]. J Am Coll Cardiol,2017,70(18):2278-2289.

[8] Szekely Y,Arbel Y. A review of interleukin-1 in heart disease: where do we stand today?[J]. Cardiol Ther,2018,7(1):25-44.

[9] Bracey NA,Beck P,Muruve D,et al. The Nlrp3 inflammasome promotes myocardial dysfunction in structural cardiomyopathy through IL-1β[J].Exp Physiol,2013,98(2):462-472.

[10] Waugh J,Perry CM. Anakinra: a review of its use in the management of rheumatoid arthritis[J]. BioDrugs,2005,19(3):189-202.

[11] Chakraborty A,Tannenbaum S,Rordorf C,et al. Pharmacokinetic and pharmacodynamic properties of canakinumab ,a human anti-interleukin-1β monoclonal antibody[J].Clin Pharmacokinet,2012,51(6):e1-e18.

[12] Blech M,Peter D,Fischer P,et al. One target-two different binding modes:structural insights into gevokizumab and canakinumab interactions to interleukin-1β[J]. J Mol Biol,2013,425(1):94-111.

[13] Tassell B,Seropian I,Toldo S,et al. Interleukin-1β induces a reversible cardiomyopathy in the mouse[J]. Inflamm Res,2013,62(7):637-640.

[14] Khoury NE,Mathieu S,Céline F. Interleukin-1β reduces L-type Ca2+,current through protein kinase C? activation in mouse heart[J].J Biol Chemi,2014,289(32):21896-21908.

[15] Harouki N,Nicol L,Remy-Jouet I,et al. The IL-1β antibody gevokizumab limits cardiac remodeling and coronary dysfunction in rats with heart failure[J]. JACC Basic Transl Sci,2017,2(4):418-430.

[16] Ibrahim NE,Januzzi JL. Established and emerging roles of biomarkers in heart failure[J]. Circ Res,2018,123(5):614-629.

[17] Abbate A,Tassell BW,Seropian I,et al. Interleukin-1β modulation using a genetically engineered antibody prevents adverse cardiac remodelling following acute myocardial infarction in the mouse[J]. Eur J Heart Fail,2010,12(4):319-322.

[18] Liu M,Chen J,Huang D,et al. A meta-analysis of proinflammatory cytokines in chronic heart failure[J]. Heart Asia,2014,6(1):130-136.

[19] 武亚琳,梁斌,杨志明.NLRP3/IL-1β途径的促动脉粥样硬化作用及临床应用[J].心血管病学进展,2019,40(6):943-946.

[20] Toldo S,Tassell BW,Abbate A. Interleukin-1 blockade in acute myocardial i nfarction and heart failure[J]. JACC Basic Transl Sci,2017,2(4):431-433.

[21] Tassell BW,Arena R,Toldo S,et al. Enhanced interleukin-1 activity contributes to exercise intolerance in patients with systolic heart failure[J]. PLoS One,2012,7(3):e33438.

[22] Tassell BW,Abouzaki N,Erdle C,et al. Interleukin-1 blockade in acute decompensated heart failure: a randomized,double-blinded,placebo-controlled pilot study[J]. J Cardiovasc Pharmacol,2016,67(6):544-551.

[23] Buckley LF,Carbone S,Trankle C,et al. Effect of interleukin-1 blockade on left ventricular systolic performance and work:,a post hoc pooled analysis of 2 clinical trials[J]. J Cardiovasc Pharmacol,2018,72(1): 68-70.

[24] Tassell BW,Arena R,Biondizoccai G,et al. Effects of interleukin-1 blockade with anakinra on aerobic exercise capacity in patients with heart failure and preserved ejection fraction (from the D-HART pilot study)[J]. Am J Cardiol,2014,113(2):321-327.

[25] Tassell BW,Trankle C,Canada J,et al. IL-1 blockade in patients with heart failure with preserved ejection fraction.[J]. Circ Heart fail,2018,11(8):e005036.

[26] Pascual-Figal D ,Bayes-Genis A ,Asensio-Lopez M,et al.The interleukin-1 axis and risk of death in patients with acutely decompensated heart failure[J]. J Am Coll Cardiol ,2019,9(73):1016-1025.

[27] Aleksova A,Beltrami AP,Carriere C,et al. Interleukin-1β levels predict long-term mortality and need for heart transplantation in ambulatory patients affected by idiopathic dilated cardiomyopathy[J]. Oncotarget,2017,8(15):25131-25140.

[28] Ridker PM,Everett BM,Thuren T,et al. Anti-inflammatory therapy with canakinumab for atherosclerotic disease[J]. N Engl J Med,2017,377(12):1119-1131.

相似文献/References:

[1]丁娟,刘地川.心力衰竭与线粒体功能障碍的研究进展[J].心血管病学进展,2016,(1):84.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.022]
　DING Juan,LIU Dichuan.Research Progress of Heart Failure and Mitochondrial Dysfunction[J].Advances in Cardiovascular Diseases,2016,(6):84.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.022]
[2]罗秀林,综述,张烁,等.肾动脉去交感神经术治疗心力衰竭——希望还是炒作[J].心血管病学进展,2016,(3):268.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.013]
　LUO Xiulin,ZHANG Shuo.Renal Sympathetic Denervation for Heart Failure—Hopes or Hypes[J].Advances in Cardiovascular Diseases,2016,(6):268.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.013]
[3]查凤艳,综述,覃数,等.心源性恶病质发病机制的研究进展[J].心血管病学进展,2016,(3):282.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.017]
　ZHA Fengyan,QIN Shu.Advances in Pathogenesis of Cardiac Cachexia[J].Advances in Cardiovascular Diseases,2016,(6):282.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.017]
[4]李慧,综述,齐国先,等.老年射血分数保留的心功能不全研究进展[J].心血管病学进展,2016,(4):354.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.007]
　LI Hui,QI Guoxian.Research Progress of Heart Failure with Preserved Ejection Fraction in Elderly People[J].Advances in Cardiovascular Diseases,2016,(6):354.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.007]
[5]亢玉,综述,张庆,等.二尖瓣瓣叶在功能性二尖瓣反流发生机制中的角色[J].心血管病学进展,2016,(4):376.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.013]
　KANG Yu,ZHANG Qing.Role of Mitral Leaflets in Pathogenesis of Functional Mitral Regurgitation[J].Advances in Cardiovascular Diseases,2016,(6):376.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.013]
[6]史秀莉,张庆,喻鹏铭.心力衰竭患者运动训练方式及其疗效的研究进展[J].心血管病学进展,2015,(5):535.[doi:10.3969/j.issn.1004-3934.2015.05.003]
　SHI Xiuli,ZHANG Qing,YU Pengming.Exercise Training Modalities and Their Treatment Effects on Patients with Heart Failure[J].Advances in Cardiovascular Diseases,2015,(6):535.[doi:10.3969/j.issn.1004-3934.2015.05.003]
[7]熊卓超,陈康玉,严激.无创血流动力学评价在心力衰竭中的应用进展[J].心血管病学进展,2019,(6):923.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.021]
　XIONG Zhuochao,CHEN Kangyu,YAN Ji.Application Progress of Noninvasive Hemodynamic Evaluation in Heart Failure[J].Advances in Cardiovascular Diseases,2019,(6):923.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.021]
[8]高薇 陈伟.铁过载性心肌病[J].心血管病学进展,2019,(5):680.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.006]
　GAO WeiCHEN Wei.Iron Overload Cardiomyopathy[J].Advances in Cardiovascular Diseases,2019,(6):680.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.006]
[9]何燕 刘育.C型利钠肽与心力衰竭[J].心血管病学进展,2019,(5):745.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.020]
　HE Yan,LIU Yu.C-type Natriuretic Peptide and Heart Failure[J].Advances in Cardiovascular Diseases,2019,(6):745.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.020]
[10]吴彤 高东来.心房颤动合并心力衰竭的射频消融治疗[J].心血管病学进展,2019,(5):757.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.023]
　WU TongGAO Donglai.Catheter Ablation of Atrial Fibrillation in Patients with Heart Failure[J].Advances in Cardiovascular Diseases,2019,(6):757.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.023]

更新日期/Last Update: 2020-09-21